Gilead Sciences, Inc. vs AbbVie Inc.
GILD wins the Tale of the Tape 7–2.
🏆 Tale of the Tape
Green = winner in each category. Higher is better except P/E (lower = cheaper).
Rolling Correlation
Moderately correlated — some diversification benefit from holding both.
Fundamentals
| Metric | GILD | ABBV |
|---|---|---|
| Market Cap | $166.9B | $384.7B |
| P/E Ratio | 18.3x | 106.2x |
| Forward P/E | 14.0x | 13.4x |
| P/B | 7.10x | -57.80x |
| Dividend Yield | 2.44% | 3.18% |
| Beta | 0.33 | 0.30 |
Quantitative Metrics
| Metric | GILD | ABBV |
|---|---|---|
| DCF Fair Value | $190.19 | $126.26 |
| DCF Upside | +36.8% | -38.9% |
| Piotroski F | 8/9 | 7/9 |
| Altman Z | 4.41 | 2.01 |
| Beneish M | -2.45 | -2.87 |
| FCF Yield | 5.05% | 4.23% |
| Net Debt/EBITDA | 1.1x | 3.0x |
| ROIC | 18.1% | 8.3% |
| WACC | 7.5% | 7.4% |
| ROIC – WACC | 10.6pp | 0.8pp |
| Gross Margin | 78.8% | 70.2% |
| Net Margin | 28.9% | 6.9% |
| Rev Growth YoY | 2.4% | 8.6% |
| Sharpe (1Y) | 1.02 | 0.61 |
| Max Drawdown 3Y | — | — |
| FCF Payout Ratio | 42% | 65% |
GILD Price
ABBV Price
ETF Exposure
GILD found in:
ABBV found in:
More Comparisons
Quant metrics computed from financial statements and 1,200+ trading days. Correlation is Pearson coefficient on daily log returns. Not investment advice.
GILD vs ABBV: Head-to-Head Analysis
Gilead Sciences, Inc. (GILD) and AbbVie Inc. (ABBV) represent two companies in the Healthcare sector. In our quantitative Tale of the Tape scoring, GILD leads 7–2 across nine fundamental and risk metrics including profitability, valuation, capital efficiency, and financial health.
In terms of capital efficiency, GILD generates a return on invested capital (ROIC) of 18.1% compared to ABBV's 8.3%. This suggests GILD is more effective at deploying capital to generate shareholder returns.
The 252-day rolling correlation between GILD and ABBV is 0.411, indicating moderate co-movement, with some diversification value from holding both in a portfolio context.
GILD appears in 40 ETFs tracked by SecuritiesDB, while ABBV appears in 38 ETFs. Investors holding broad-market ETFs may already have indirect exposure to both stocks.
Frequently Asked Questions
Which stock is the better investment, GILD or ABBV?
Our quantitative analysis compares GILD and ABBV across nine fundamental dimensions. GILD wins the Tale of the Tape 7–2. However, stock selection depends on your individual risk tolerance, time horizon, and portfolio context. These metrics are computed from SEC filings and market data — they are not investment recommendations.
Are GILD and ABBV correlated?
The 252-day correlation between GILD and ABBV is 0.411. They show moderate correlation — partially diversifying.
How is the Tale of the Tape scored?
The Tale of the Tape compares both stocks across nine categories: profitability (net margin), valuation (P/E), efficiency (ROIC), health (Piotroski F-Score), safety (Altman Z-Score), growth (revenue YoY), risk (Sharpe ratio), leverage (debt-to-equity), and cash generation (FCF yield). The stock that wins more categories takes the overall score. Lower P/E and lower debt-to-equity count as wins.